UNSPSC 51422340: Dexamethasone phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2BP70L44PR, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(dihydrogen phosphate) but more generally known as dexamethasone phosphate, which bears US NIH Compound Identifier 9400. European Medicines Agency schedules Dexamethasone phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01612MIG.

UNSPSC 51422340 Dexamethasone phosphate is a Commodity code whose recent state and local activity does not align with its nominal scope. Dexamethasone phosphate is a corticosteroid pharmaceutical, but the only recent state and local opportunity tagged to this code—Seminole County, Florida's IFB 60459723LAS for Naloxone and Safe Drug Deactivation Systems—solicits opioid-overdose reversal medication and drug disposal equipment, not corticosteroids. The mismatch suggests either a classification error in the county's tagging or a divergence between the code's intent and current procurement practice.

Seminole County, Florida issued the IFB on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding with a response deadline of July 26, 2023. Quarterly deliveries are required to the Seminole County Community Health Building in Sanford, with vendors responsible for all shipping and delivery costs. The contract runs two years with a one-year renewal option, includes a three-month probationary termination clause, and is potentially FEMA-funded, introducing federal compliance requirements. The source shows no other recent state and local opportunities under this code, leaving insufficient activity to characterize issuing-body patterns, geographic concentration, or repeat-buyer trends across jurisdictions.